PARNAXLAB — Parnax Lab Share Price
Last trade - 00:00- IN₹1.19bn
- IN₹2.00bn
- IN₹2.49bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.25 | ||
| Price to Tang. Book | 1.26 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.47 | ||
| EV to EBITDA | 8.77 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 10.95% | ||
| Return on Equity | 10.04% | ||
| Operating Margin | 5.72% | ||
Financial Summary
| Year End 31st Mar | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 1,630.32 | 1,676.07 | 1,887.11 | 1,877.38 | 2,485.44 | n/a | n/a | 22.51% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | -19.24 | +6.72 | +22.14 | +16.93 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Parnax Lab Limited is an India-based holding company. The Company is principally engaged in the business activities of manufacturing and export of pharmaceutical formulations. The Company operates through the trading of the pharmaceuticals and medicinal products segment. It is engaged in developing and delivering huge volumes of oral formulations, such as cough expectorants, antacids, antihistamines, multi-vitamins, enzyme preparations, pediatric formulations, special formulations for geriatrics, viscous products, suspensions, and others. Its product portfolio consists of pharmaceuticals, cosmetics, herbal, and nutraceuticals. Its cosmetics products include antidruf gel, EVE fairness acne care night cream for acne skin, EVE fairness scrub, and others. The Company provides companies with the service of developing the drug through Contract Research and Manufacturing Services (C.R.A.M.S) or manufacturing collaborations. The Company’s subsidiary is Naxpar Pharma Private Limited.
Directors
- Prakash Shah CHM
- Baiju Shah CFO
- Preet Kukreja CCO
- Ami Shah NED
- Tirunillai Anatharaman NID
- Vindyak Desai NID
- Yogesh Varia NID (67)
- Last Annual
- March 31st, 2026
- Last Interim
- June 30th, 2026
- Incorporated
- August 3rd, 1982
- Public Since
- September 15th, 2009
- No. of Shareholders
- 3,809
- No. of Employees
- 12
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 11,485,616
- Address
- GALA NO 114 BLDG NO 8, MUMBAI, 400022
- Web
- https://naxparlab.com/
- Phone
- +91 2230015666
- Auditors
- C. N. Patel & Co.
Similar to PARNAXLAB
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
As of Today at 22:37 UTC, shares in Parnax Lab are trading at IN₹103.50. This share price information is delayed by 15 minutes.
Shares in Parnax Lab last closed at IN₹103.50 and the price had moved by over the past 365 days. In terms of relative price strength the Parnax Lab share price has matched the S&P BSE 100 Index by over the past year.
There is no consensus recommendation for this security.
Find out moreParnax Lab does not currently pay a dividend.
Parnax Lab does not currently pay a dividend.
Parnax Lab does not currently pay a dividend.
To buy shares in Parnax Lab you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹103.50, shares in Parnax Lab had a market capitalisation of IN₹1.19bn.
Here are the trading details for Parnax Lab:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: PARNAXLAB
Based on an overall assessment of its quality, value and momentum Parnax Lab is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Parnax Lab. Over the past six months, its share price has matched the S&P BSE 100 Index by .
As of the last closing price of IN₹103.50, shares in Parnax Lab were trading -14.26% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Parnax Lab PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹103.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Parnax Lab's management team is headed by:
- Prakash Shah - CHM
- Baiju Shah - CFO
- Preet Kukreja - CCO
- Ami Shah - NED
- Tirunillai Anatharaman - NID
- Vindyak Desai - NID
- Yogesh Varia - NID